Prevalence of altered mismatch repair protein nuclear expression detected by immunohistochemistry on adenomas with high-grade dysplasia and features associated with this risk in a population-based study.
Basterra M, Gomez M, Mercado Mdel R, Irisarri R, Amorena E, Arrospide A, Montes M, Aisa G, Cambra KI, Urman J.
Gastroenterol Hepatol. 2016 Oct;39(8):500-7
Colorectal cancer health services research study protocol: the CCR-CARESS observational prospective cohort project.
Quintana JM, Gonzalez N, Anton-Ladislao A, Redondo M, Bare M, Fernandez de Larrea N, Briones E, Escobar A, Sarasqueta C, Garcia-Gutierrez S, Aguirre U; REDISSEC-CARESS/CCR Group.
BMC Cancer. 2016 Jul 8;16:435.
Economic evaluation of the breast cancer screening programme in the Basque Country: retrospective cost-effectiveness and budget impact analysis.
Arrospide A, Rue M, van Ravesteyn NT, Comas M, Soto-Gordoa M, Sarriugarte G, Mar J.
BMC Cancer. 2016 Jun 1;16:344. Factor de impacto: 3.36.
Cost-utility analysis of an integrated care model for multimorbid patients based on a clinical trial.
Lanzeta I, Mar J, Arrospide A.
Gac Sanit. 2016;30:352-8. Factor de impacto: 1.186.
Evaluation of the implementation of an integrated program for musculoskeletal system care.
Larrañaga I, Soto-Gordoa M, Arrospide A, Jauregui ML, Millas J, San Vicente R, Aguirrebeña J, Mar J.
Reumatol Clin. 2016 Jun 16. pii: S1699-258X(16)30044-4. doi: 10.1016/j.reuma.2016.04.014. [Epub ahead of print].
Advanced prostate cancer survival in Spain according to the Gleason score, age and stage.
Campa J, Mar-Barrutia G, Extramiana J, Arrospide A, Mar J.
Actas Urol Esp. 2016;40(8):499-506. Factor de impacto: 1.022
Minimum intravenous thrombolysis utilization rates in acute ischemic stroke to achieve population effects on disability: A discrete-event simulation model
Hoffmeister L, Lavados PM, Mar J, Comas M, Arrospide A, Castells X.
Journal of the Neurologicas Science. 2016; 365: 59-64. doi: 10.1016/j.jns.2016.04.005. Factor de impacto: 2.474.
Economic impact of patients admitted to stroke units in Spain.
Alvarez-Sabín J, Quintana M, Masjuan J, Oliva-Moreno J, Mar J, Gonzalez-Rojas N, Becerra V, Torres C, Yebenes M; CONOCES Investigators Group.
Eur J Health Econ. 2016. Epub ahead of print.
Cost-effectiveness analysis of simeprevir with daclatasvir for non-cirrhotic genotype-1b-naïve patients plus chronic hepatitis C.
Gimeno-Ballester V, Mar J, San Miguel R.
Expert Rev Pharmacoecon Outcomes Res. 2016; 16(2): 285-94.
Proposal to inform European institutions regarding the regulation of conscientious objection to abortion.
Lertxundi R, Ibarrondo O, Merki-Feld GS, Rey-Novoa M, Rowlands S, Mar J.
Eur J Contracept Reprod Health Care. 2016 Mar 17:1-3.
Análisis coste efectividad del tratamiento de la hepatitis C crónica con Sofosbuvir-Simeprevir en pacientes genotipo 1 y fibrosis avanzada.
Mar J, Mar-Barrutia L, Gimeno-Ballester V, San Miguel R.
Med Clinica (Barc). 2016;146:61-4. Factor de impacto: 1,385.
Incorporating Budget Impact Analysis in the Implementation of Complex Interventions: A Case of an Integrated Intervention for Multimorbid Patients within the CareWell Study.
Soto-Gordoa M, Arrospide A, Merino Hernández M, Mora Amengual J, Fullaondo Zabala A, Larrañaga I, de Manuel E, Mar J; [on behalf of the CareWell group].
Value Health. 2017 Jan;20(1):100-106
The cost of colorectal cancer according to the TNM stage
Mar J, Errasti J, Soto-Gordoa M, Mar-Barrutia G, Martinez-Llorente JM, Domínguez S, García-Albás JJ, Arrospide A.
Cir Esp. 2017 Feb;95(2):89-96.
Sofosbuvir plus simeprevir for the treatment of Genotype 1 chronic hepatitis C: a review of evidence
Gimeno-Ballester V, Simón MÁ, Trigo C, Mar J, San Miguel R.
Expert Rev Gastroenterol Hepatol. 2016;10(11):1289-1303.
